With the theme "towards a new era of biological economy: innovation, benefitting human and sustainable development", the 12th China Bioindustry Convention kicked off at Guangzhou Baiyun International Convention Center on June 10th.
In order to create a platform for scientific research institutions and pharmaceutical companies to discuss potential cooperation, a docking meeting was held during the convention.
“In my opinion, bioindustry development in Guangzhou currently lags behind the world standard,” said Dr. Zhong Nanshan, Academician of Chinese Academy of Engineering. “The Guangdong-Hong Kong-Macao Greater Bay Area is a good platform to boost the development of Guangzhou’s bioindustry, as long as we strengthen ourcooperation with institutions and companies in Hong Kong and Macao.”
Dr. Zhong Nanshan, Academician of Chinese Academy of Engineering
“As far as I am concerned, the standard of Guangzhou’s bioindustry ought to meet existing international standards within two or three years.” Zhong added.
Guangdong is currently outlining its 13th five-year plan for bioindustry development. By 2020, a competitive bio-economic group will come into being with an industry value estimated to exceed 500 billion yuan.
In terms of IAB industry, Guangzhou is underway on a five-year action plan from 2018 to 2022. It will strive to make the output value of its IAB industries hit one trillion RMB by 2022, when it is believed industry clusters will take a leading role in China and exert global influence.
Shi Pengfei, Associate Counsel of Guangzhou Municipal Science and Technology Bureau indicated that the docking meeting aims to promote the commercialization of research findings.
“I hopes that more scientific research institutions and companies can support the development of Guangzhou’s bioindustry.” said Shi.
The convention also featured a founding ceremony of the Guangdong-Hong Kong-Macao Greater Bay Area High-Performance Medical Equipment Innovation Center, as well as a signing ceremony for an advanced research institute to be jointly launched by the Chinese University of Hong Kong and the Guangzhou Regenerative Medicine and Health Guangdong Laboratory.
Author: Steven Yuen, Lijiaxing
Editor: Simon Haywood